WO2000016753A3 - Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika - Google Patents

Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika Download PDF

Info

Publication number
WO2000016753A3
WO2000016753A3 PCT/DE1999/002944 DE9902944W WO0016753A3 WO 2000016753 A3 WO2000016753 A3 WO 2000016753A3 DE 9902944 W DE9902944 W DE 9902944W WO 0016753 A3 WO0016753 A3 WO 0016753A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleobases
nucleosides
derivatives
reducing
cytostatic agents
Prior art date
Application number
PCT/DE1999/002944
Other languages
English (en)
French (fr)
Other versions
WO2000016753A2 (de
Inventor
Iduna Fichtner
Peter Langen
Original Assignee
Max Delbrueck Centrum
Iduna Fichtner
Peter Langen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Iduna Fichtner, Peter Langen filed Critical Max Delbrueck Centrum
Priority to EP99969331A priority Critical patent/EP1037618A1/de
Publication of WO2000016753A2 publication Critical patent/WO2000016753A2/de
Publication of WO2000016753A3 publication Critical patent/WO2000016753A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Nucleosiden, Nucleobasen und deren Derivaten, insbesondere von 6-Methyluracil, zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika sowie Kombinationspräparate von Nucleosiden, Nucleobasen und deren Derivaten und Cytostatika, insbesondere Carboplatin.
PCT/DE1999/002944 1998-09-17 1999-09-16 Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika WO2000016753A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP99969331A EP1037618A1 (de) 1998-09-17 1999-09-16 Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19842578.3 1998-09-17
DE1998142578 DE19842578A1 (de) 1998-09-17 1998-09-17 Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika

Publications (2)

Publication Number Publication Date
WO2000016753A2 WO2000016753A2 (de) 2000-03-30
WO2000016753A3 true WO2000016753A3 (de) 2000-09-14

Family

ID=7881265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/002944 WO2000016753A2 (de) 1998-09-17 1999-09-16 Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika

Country Status (3)

Country Link
EP (1) EP1037618A1 (de)
DE (1) DE19842578A1 (de)
WO (1) WO2000016753A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10117615A1 (de) * 2001-04-07 2002-10-10 Max Delbrueck Centrum Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zur verbesserten Gewinnung von adulten Stammzellen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023506A1 (de) * 1995-02-01 1996-08-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023506A1 (de) * 1995-02-01 1996-08-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FELIU, J. ET AL: "Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin: A phase II study of the ONCOPAZ cooperative group", CANCER (N. Y.) (1996), 78(2), 211-216, 1996, XP000913477 *
HOFS, H. P. ET AL: "Potentiation of cisplatin antitumor activity by ethyldeshydroxysparsomycin in L1210 leukemia", ANTICANCER RES. (1992), 12(1), 167-70, 1992, XP000910656 *
IVANOVA, R. K.: "Effect of orotic acid on thrombocytopoiesis in guinea pigs with acute posthemorrhagic anemia", PATOL. FIZIOL. EKSP. TER. (1969), 13(2), 71-2, 1969, XP000910557 *
SUGA, SHOJI ET AL: "Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin", INTERN. MED. (TOKYO) (1996), 35(12), 930-936, 1996, XP000910645 *
TSUNODA, AKIRA ET AL: "Repeated administration of low-dose cisplatin simultaneous with uracil and tegafur against autochthonous colon cancer in rats", SHOWA UNIV. J. MED. SCI. (1998), 10(1), 41-49, 1998, XP000910628 *
VILLALON, ANTONIO H. ET AL: "A comparative, randomized trial of UFT and 5-fluorouracil and combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at the Philippines General Hospital", ONCOLOGY (1996), VOLUME DATE 1997, 54(SUPPL. 1), 2-6, 1996, XP000910623 *
ZYLICZ, Z. ET AL: "Potentiation of cisplatin antitumor activity on L1210 leukemia s.c. by sparsomycin and three of its analogs", CANCER LETT. (SHANNON, IREL.) (1989), 46(2), 153-7, 1989, XP000910681 *

Also Published As

Publication number Publication date
WO2000016753A2 (de) 2000-03-30
EP1037618A1 (de) 2000-09-27
DE19842578A1 (de) 2000-03-23

Similar Documents

Publication Publication Date Title
AP1411A (en) Pyrrolo[2,3d] pyrimidine compositions and their use.
AU2795000A (en) Epothilone derivatives and their use as antitumor agents
DE69716135D1 (en) In 6-position durch thio substituierte paclitaxele
AU2001282399A1 (en) Resorcinol derivatives
MXPA02001508A (es) Derivados de arilmetil-carbonilamino-tiazol y sus usos como agentes antitumorales.
IL142372A0 (en) 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
MY117805A (en) Resorcinol derivatives
ZA982523B (en) Di-aryl ethers and their derivatives as anti-cancer agents.
MXPA02001497A (es) Derivados de 3-(5)-ureido-pirazol, procedimiento para su preparacion y sus uso como agentes antitumorales.
HUP0104200A3 (en) 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents
IL144964A0 (en) Methods of treatment of mitochondrial disorders
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
WO2002024613A3 (en) Resorcinol derivatives
AU7124398A (en) Biflavinoids and derivatives thereof as antiviral agents, alone or in combination with at least one known antiviral agent
HK1041482A1 (en) Naphtho-and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents.
NO985307D0 (no) Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvendelse som antitumor- og antivirale midler
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU2002366736A1 (en) Masked phosphate containing nucleoside derivatives and their use as antivirals
AP2001002274A0 (en) Rescorcinol derivatives.
MXPA02012263A (es) 5-aminoalquil-pirazol[4,3-d]pirimidinas.
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
WO2000016753A3 (de) Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika
WO2002008204A3 (en) 5-substituted pyrimidine derivatives of conformationally locked nucleoside analogues
EP0979650A4 (de) Antivirus mittel
AU3251597A (en) Composition and methods for modulating the length of telomeres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999969331

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 1999969331

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999969331

Country of ref document: EP